RADX_OUT_1 [2025-04-17 10:10:50 -0400] 3042 Bytes | 769 tokens | Cum: 769 tkns (9.61% of 8k)
==========================================================================

Booyah, my friends! It's already 10:10:49 AM on Thu Apr 17, 2025 -0400, and I've got my eyes locked on Radiopharm Theranostics (RADX), pushing up to 5.2800 from 4.2000. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Radiopharm Theranostics (RADX)
IPO: 2024-11-27 (4 Months Ago)
Market Cap: $34,854,104
Shares Outstanding: 2,333,980,000
Exchange: XNAS
Description: Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Here’s a list of headlines for Radiopharm Theranostics:

Mar-27-25 03:13PM - Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
Mar-17-25 08:56AM - New RAD202 Data Confirms Positive Tumor Uptake and Favorable Biodistribution
Feb-10-25 08:00AM - New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases
Jan-10-25 08:00AM - Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
Dec-30-24 08:00AM - Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
Dec-20-24 08:00AM - RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Nov-27-24 08:00AM - Radiopharm Achieves Nasdaq Listing of American Depositary Shares

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Radiopharm Theranostics (RADX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

RADX_OUT_3 [2025-04-17 10:10:51 -0400] 761 Bytes | 221 tokens | Cum: 992 tkns (12.40% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-11T21:06:36Z - 12 Health Care Stocks Moving In Friday's After-Market Session - 180 Life Sciences (NASDAQ:ATNF), Acl...
A2 - 2025-03-27T19:16:03Z - Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting (RADX)...
A3 - 2025-03-24T21:05:45Z - 12 Health Care Stocks Moving In Monday's After-Market Session - Aspira Womens Health (NASDAQ:AWH), C...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RADX_OUT_5 [2025-04-17 10:10:51 -0400] 1181 Bytes | 357 tokens | Cum: 1351 tkns (16.89% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Friday's After-Market Session - 180 Life Sciences (NASDAQ:ATNF), Aclarion (NASDAQ:ACON)**Date: 2025-04-11Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44774972/12-health-care-stocks-moving-in-fridays-after-market-sessionGainers OneMedNet ONMD shares rose 15.3% to $0.52 during Friday's after-market session. The market value of their outstanding shares is at $14.5 million. Wellgistics Health WGRX stock rose 14.18% to $3.3. The market value of their outstanding shares is at $171.4 million. Aclarion ACON stock rose 11.52% to $9.29. The company's market cap stands at $4.7 million. As per the news, the Q4 earnings report came out 2 days ago. 180 Life Sciences ATNF stock increased by 10.95% to $0.95. The company's market cap stands at $3.6 million. Titan Pharma TTNP stock rose 10.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RADX_OUT_7 [2025-04-17 10:10:52 -0400] 1181 Bytes | 350 tokens | Cum: 1703 tkns (21.29% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): 8% to $4.0. The company's market cap stands at $3.6 million. Radiopharm Theranostics RADX stock increased by 10.11% to $4.9. The market value of their outstanding shares is at $38.1 million. Losers Longevity Health Holdings XAGE shares decreased by 18.5% to $0.11 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. Climb Bio CLYM shares declined by 11.72% to $1.13. The company's market cap stands at $76.2 million. Citius Oncology CTOR shares decreased by 8.97% to $0.61. The market value of their outstanding shares is at $43.7 million. Virax Biolabs Group VRAX stock declined by 7.28% to $1.02. The market value of their outstanding shares is at $4.4 million. Pasithea Therapeutics KTTA stock fell 7.05% to $1.32. The company's market cap stands at $3.5 million. Soligenix SNGX shares decreased by 6.67% to $2.03. The company's market cap stands

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RADX_OUT_9 [2025-04-17 10:10:53 -0400] 1137 Bytes | 375 tokens | Cum: 2080 tkns (26.00% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): at $6.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACONAclarion Inc$9.288.16%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum-Growth11.25Quality-Value65.12Price TrendShortMediumLongOverviewATNF180 Life Sciences Corp$0.820018.7%CLYMClimb Bio Inc$1.13-2.59%CTORCitius Oncology Inc$0.6112-1.28%KTTAPasithea Therapeutics Corp$1.33-16.9%ONMDOneMedNet Corp$0.5163-2.58%RADXRadiopharm Theranostics Ltd$4.9011.9%SNGXSoligenix Inc$2.037.41%TTNPTitan Pharmaceuticals Inc$4.006.10%VRAXVirax Biolabs Group Ltd$1.0216.4%WGRXWellgistics Health Inc$3.30-15.6%XAGELongevity Health Holdings Inc$0.1100-14.5%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RADX_OUT_11 [2025-04-17 10:10:54 -0400] 238 Bytes | 59 tokens | Cum: 2141 tkns (26.76% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RADX_OUT_13 [2025-04-17 10:11:06 -0400] 4963 Bytes | 1181 tokens | Cum: 3324 tkns (41.55% of 8k)
==========================================================================

This is our set of metrics for Radiopharm Theranostics.
Please analyze the numbers.

+---------------------+----------------------+------------------------+----------------------+
| Volume: 1,880 | Perf Month: -21.48% | Option/Short: No / Yes | Sales Y/Y TTM: 0.57% |
+---------------------+----------------------+------------------------+----------------------+
| Avg Volume: 195.40K | Perf Quarter: -7.71% | Short Float: - | ROE: -111.73% |
+---------------------+----------------------+------------------------+----------------------+
| Rel Volume: 0.09 | Index: - | Short Ratio: 0.25 | ROI: -83.91% |
+---------------------+----------------------+------------------------+----------------------+
| RSI (14): 48.88 | Market Cap: 37.27M | Short Interest: 0.05M | Sales Surprise: - |
+---------------------+----------------------+------------------------+----------------------+
| ATR (14): 0.72 | Shs Outstand: 7.34M | Beta: - | EPS Surprise: - |
+---------------------+----------------------+------------------------+----------------------+
| SMA20: 0.02% | Shs Float: - | Sales Q/Q: - | P/E: - |
+---------------------+----------------------+------------------------+----------------------+
| SMA50: -6.74% | Inst Own: 5.60% | Sales past 5Y: -0.10% | Earnings: Feb 28 AMC |
+---------------------+----------------------+------------------------+----------------------+
| SMA200: -10.61% | Insider Own: - | Employees: - | |
+---------------------+----------------------+------------------------+----------------------+
| Perf Week: 9.36% | Insider Trans: - | Debt/Eq: 0.00 | |
+---------------------+----------------------+------------------------+----------------------+

The next section covers any insider trading by Radiopharm Theranostics officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 5.28
Average Volume: 39475.83
30-Day High: 6.1
30-Day Low: 3.89
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Radiopharm Theranostics (RADX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Radiopharm Theranostics.

2) MARKET_SCORE[]
This conversation was initiated because RADX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for RADX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, RADX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect RADX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Radiopharm Theranostics.

11) ETHICAL_RATING[]
Rate Radiopharm Theranostics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Radiopharm Theranostics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

RADX_IN_15 [2025-04-17 10:11:06 -0400] 126 Bytes | 29 tokens | Cum: 3560 tkns (44.50% of 8k)
==========================================================================

====================================
[2025-04-17 10:11:06] # Analysis Completed
Elapsed Time: 17.01 seconds